STATEMENT BY THE BOARD OF DIRECTORS OF KARO PHARMA AKTIEBOLAG IN RELATION TO THE INCREASED PUBLIC OFFER FROM EQT VIII, THROUGH KARO INTRESSENTER AB
The Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag accept the increased public offer made by EQT VIII, through Karo Intressenter AB.Background This statement is made by the Board of Directors[1](the “Board of Directors”) of Karo Pharma Aktiebolag (the “Company” or “Karo Pharma”) pursuant to Rule II.19 of Nasdaq Stockholm’s takeover rules (the “Takeover Rules”). On 29 October 2018, EQT VIII (“EQT VIII”)[2], through the indirectly wholly owned subsidiary Karo Intressenter AB[3] (“Karo Intressenter” or